Will 2021 add more glow to these healthcare stocks?

February 08, 2021 08:22 AM PST | By Team Kalkine Media

Will 2021 add more glow to these healthcare stocks?

Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson is an American multinational medical device company operating out of New Brunswick, New Jersey. This blue-chip pharma stock develops medical devices, pharmaceuticals, and various packaged goods.

JNJ is also developing a coronavirus vaccine for which it has recently submitted an emergency use authorization (EUA) application. Johnson & Johnson is developing the vaccine through its biotech firm Janssen Biotech. The company also revealed its investigational single-dose vaccine is ready to be shipped immediately once it receives the authorization.

According to JNJ, its vaccine reduces the severity of COVID-19 symptoms, which would help lower the number of patients in the hospitals. The high number of patients has increased the pressure on healthcare systems globally. If the vaccine is approved, Johnson & Johnson would be a serious contender giving tough competition to other vaccine makers worldwide.

Johnson & Johnson also reported strong revenue performance last week. The company added USD 22 billion to its books, making it a stock worth watching in 2021.

Johnson & Johnson (NYSE:JNJ) share price last traded at USD 164.92, up 0.29% as on 8 February 2021, 4:00PM EST.

Moderna Inc. (NASDAQ:MRNA)

Moderna is one of the widely known biotech stocks of 2020. The American pharmaceutical and biotechnology company focuses on drug research and development and produces various vaccine technologies. It operates from Cambridge, Massachusetts.

The company gained a lot of traction because of its COVID-19 vaccine development announcements, offering many hopes to the world. Moderna is one of the few companies offering authorized vaccines for emergency use in the US. The biotech company recently announced two positive developments for which stock price rallied.

While Singapore accepted its interim authorization for COVID-19 vaccine, Switzerland increased the order of its vaccine by 6 million doses. Moderna states that international approval adds global credibility to its vaccine.

Moderna faced neck-and-neck competition from another American pharma company Pfizer Inc. (NYSE:PFE) to develop and roll out COVID-19 vaccine. Notably, with its sale of vaccine doses, Moderna is estimated to clock in more than USD 11 billion in 2021. There is a strong possibility that the company will see significant recurring revenues as well.

Moderna Inc. (NASDAQ:MRNA) share price last traded at USD 185.98, up 5.53% as on 8 February 2021, 4:00PM EST.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

This American biotechnology company is another company that has sprung to spotlight in the healthcare segment. Regeneron Pharmaceuticals, Inc. is based out of Westchester County, New York and develops medicines for serious diseases. Regeneron is a leading player in the biotech industry, and its stock witnessed one of the best years in 2020.

Regeneron released its earnings report recently, which seems to have pleased the investors. Looking at the company’s performance, 2021 seems like another great year for REGN stock.

In the fourth-quarter report, Regeneron informed investors of having clocked a total revenue of USD 2.42 billion. It is a 30% growth year-over-year. Additionally, the company posted earnings per share (EPS) of USD 10.24. The biotech company noted that its eye disease treatment - Eylea, saw improved demand in the market. That fetched the company sales of USD 1.34 billion in quarter four.

Similarly, global net sales for its eczema drug Dupixent also increased to 56% year-over-year, which added USD 1.17 billion to sales. Regeneron also has various other products in the pipeline for clinical development.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) share price last traded at USD 494.90, down 0.82% as on 8 February 2021, 4:00PM EST.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.